Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 10c, Revenues Miss
November 5, 2020 5:34 PM ESTXenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.25), $0.10 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $6.55 million versus the consensus estimate of $10.06 million.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make good progress as we advance our proprietary neurology product candidates into mid- to late-stage clinical development despite the ongoing COVID-19 pandemic. We continue to manage our business prudently and are in a very sound financial position... More
